Transaction overview

ProSites Inc., a portfolio company of Rockbridge Growth Equity and provider of marketing services for veterinary practices, acquired GeniusVets on December 17, 2025. While financial details were not disclosed, the deal aims to create a comprehensive veterinary marketing platform under ProSites' LifeLearn brand. The transaction was announced simultaneously with its closing.

Deal structure and financing

The acquisition's exact equity-to-debt split remains undisclosed. However, Copper Run Capital and Lane Four Capital Partners served as buy-side advisors in securing financing for the deal from NXT Capital and Manulife. No information is available regarding any lock-up terms or IPO optionality tied to this transaction. The sell-side was advised by 733 Park.

Strategic context

ProSites acquired GeniusVets to expand its LifeLearn brand, which provides digital marketing and client communication solutions for veterinary practices. This move seeks to capitalize on growing demand for specialized veterinary services communications tools. GeniusVets' advanced digital marketing capabilities will complement LifeLearn's existing AI-powered offerings, enabling veterinarians to better manage their marketing campaigns.

The acquisition marks a strategic shift by Rockbridge Growth Equity in its portfolio company ProSites, allowing it to enhance its service suite and strengthen market position within the veterinary sector. For GeniusVets, divestiture to ProSites aligns with broader goals of scaling operations while maintaining alignment with a partner that shares similar growth ambitions.

Regulatory path

As both companies are based in the United States, regulatory scrutiny primarily involved antitrust filings with the U.S. Federal Trade Commission (FTC) and the Antitrust Division of the Department of Justice under Hart-Scott-Rodino (HSR) Act requirements. No specific remedial measures were required to facilitate this transaction. HSR filing details are not publicly available, but given the nature of the deal's undisclosed value, it likely cleared regulatory hurdles without significant delays or conditions.